Progestin Tx reasonably effective for early endometrial cancer

Progestin tx reasonably effective for early endometrial cancer
Conservative management with oral progestin can be a reasonable treatment option for many patients with stage 1A endometrial cancer, according to research published in the July issue of Obstetrics & Gynecology.

(HealthDay)—Conservative management with oral progestin can be a reasonable treatment option for many patients with stage 1A endometrial cancer, according to research published in the July issue of Obstetrics & Gynecology.

Jeong-Yeol Park, M.D., Ph.D., from the University of Ulsan in Korea, and colleagues reviewed the medical records of 48 women (age 40 years or younger) with endometrioid adenocarcinoma of the uterus who were treated conservatively with oral .

The researchers found that 14 (29.2 percent) received daily oral megestrol acetate (median dose, 160 mg per day) and 34 patients (70.8 percent) received daily oral medroxyprogesterone acetate (median dose, 500 mg per day). After the median treatment duration of 10 months, 37 patients (77.1 percent) had complete responses. For patients with stage IA, grade 2 to 3 without myometrial invasion (17 patients), complete response was 76.5 percent; for patients with stage IA, grade 1 with superficial myometrial invasion (23), complete response was 73.9 percent; and for patients with stage IA, grade 2 to 3 with superficial myometrial invasion (eight), complete response was 87.5 percent). After a median follow-up time of 48 months, recurrence rates for 37 patients who had achieved a complete response were 23.1, 47.1, and 71.4 percent, respectively. No disease progression or death from the disease occurred. Nine patients gave birth to 10 healthy newborns.

"Progestin treatment appears to be reasonably effective for patients with stage IA, grade 2 to 3 differentiation without myometrial invasion and patients with stage IA grade 1 differentiation with superficial myometrial invasion," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Chemo combination promising for multiple myeloma

May 02, 2012

(HealthDay) -- For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response ...

Prognostic factors identified in mucoepidermoid carcinoma

Aug 10, 2012

(HealthDay) -- Diagnosis of low- or intermediate-grade tumors is associated with significantly better overall survival and disease-free survival in patients with mucoepidermoid carcinoma (MEC) of the salivary ...

Recommended for you

Tips, myths surrounding breastfeeding

17 hours ago

Breastfeeding is the method of infant feeding recommended by the Association of Women's Health, Obstetric and Neonatal Nurses, the American Academy of Pediatrics and the American College of Obstetricians and ...

Joint effort in standardizing due date estimation

Sep 23, 2014

(HealthDay)—The American College of Obstetricians and Gynecologists, the American Institute of Ultrasound in Medicine, and the Society for Maternal-Fetal Medicine have jointly released new recommendations ...

AWHONN recommends reducing overuse of labor induction

Sep 23, 2014

The Association of Women's Health, Obstetric and Neonatal Nurses (AWHONN) is calling upon healthcare providers and pregnant women to avoid induction of labor at any time during pregnancy unless it is medically necessary.

User comments